Buch, Englisch, 484 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 1930 g
Reihe: Contemporary Biomedicine
Buch, Englisch, 484 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 1930 g
Reihe: Contemporary Biomedicine
ISBN: 978-0-89603-210-1
Verlag: Humana Press
Cellular Cancer Markers provides a status report for markers of tumor cell activation, proliferation, and longevity that makes possible an informed judgment regarding the value of many newly proposed tumor markers. It also offers insight into the latest approaches to diagnosing cancer and an appreciation of how these marker-based tests can clarify the prognosis of cancer.
Zielgruppe
Professional/practitioner
Autoren/Hrsg.
Fachgebiete
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizin, Gesundheitswesen Biomedizin, Medizinische Forschung, Klinische Studien
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Medizinische Fachgebiete Pathologie, Cytopathologie, Histopathologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Vorklinische Medizin: Grundlagenfächer Molekulare Medizin, Zellbiologie
- Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Onkologie, Krebsforschung
Weitere Infos & Material
Ch. 1. Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer.- Ch. 2. ras Proto-Oncogene Activation in Human Malignancy.- Ch. 3. C-myc as a Tumor Marker for Primary Human Cancers.- Ch. 4. p53 in Human Cancer.- Ch. 5. Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies.- Ch. 6. Genetic Alterations in Colon Cancer.- Ch. 7. Genetic Changes in Breast Cancer.- Ch. 8. Genetic Alterations in Lung Cancer.- Ch. 9. Wilms Tumor-Susceptibility Loci.- Ch. 10. Non-Hodgkin’s Lymphomas.- Ch. 11. Phenotypic Expression of Hodgkin’s Disease: Biologic, Immunologic, and Functional Properties of Reed-Sternberg Cells.- Ch. 12. Melanoma Markers.- Ch. 13. Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma.- Ch. 14. P-Glycoproteins in Tumors.- Ch. 15. Genetically Engineered Antitumor Monoclonal Antibodies.- Ch. 16. Targeting Antisense Oligonucleotide Chemotherapy to the Type I Regulatory Subunit of cAMP-Dependent Protein Kinase.- Ch. 17. Summary and Perspective: Assessing Test Effectiveness—The Identification of Good Tumor Markers.